C•Therapeutics
Pioneering Precision Oncology
Explore our cutting-edge portfolio of antibodies and ADCs designed to revolutionize cancer therapy.
About
C•Therapeutics is a biotech focused on multimodal oncology in the pre-clinical stage that wants to break the barriers of traditional drug development by incorporating new therapeutic targets, seeking novel solutions that can reach the clinic as soon as possible, which is why we aspire to overcome some of the greatest challenges of current oncology.
What is an ADC?
An ADC, or Antibody-Drug Conjugate, is a sophisticated therapeutic approach that combines the precision targeting of monoclonal antibodies with the potent cytotoxic effects of chemotherapy drugs. This technology allows for the selective delivery of cytotoxic agents directly to cancer cells, sparing healthy tissues and minimizing systemic toxicity.
Benefits of ADCs
Precision Targeting
ADCs specifically recognize and bind to tumor-specific antigens, delivering the cytotoxic payload directly to cancer cells while sparing healthy tissues.
Enhanced Efficacy
By precisely targeting cancer cells, ADCs can deliver a higher concentration of the cytotoxic drug to the tumor site, resulting in increased efficacy and improved patient outcomes.
Reduced Side Effects
The targeted delivery of chemotherapy minimizes off-target effects, leading to reduced systemic toxicity and improved tolerability for patients.
"Check our pipeline to see the progress we are making with the development of two new monoclonal antibodies in addition to the ADC that is currently in development."
We Are a People Driven Team
We have a great team with experience and knowledge for the development of Antibodies and ADCs.
If you are interested in learning more about our scientific work, do not hesitate to contact us.
News & Scientific Papers
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Contact
info@ctherapeuticsgroup.com